Biotech ETF Could Run to $100

By
A A A
Share |

 

iShares Nasdaq Biotechnology Index Fund ( IBB ) -- The goal of this exchange-traded fund ( ETF ) is to provide investment results that correspond generally to the price-and-yield performance of the Nasdaq Biotechnology Index ( NBI ).   

IBB Chart  

Chart Legend  

In short, biotech stocks have broken out from a type of triple-top on a broad accumulation. 

This breakout represents a 17-month high with an eventual target of $95 to $100. 

The stochastic and other internal indicators are overbought, and investors may want to wait to buy IBB on a pullback to $85, but the course is clear, and that is definitely up.

Related Articles:

FREE Stock Picks Every Week!
Get the hottest stocks to buy and sell delivered right to your e-mail inbox every week! Start now.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Investing Ideas

Referenced Stocks: ETF , IBB

Sam Collins

Sam Collins

More from Sam Collins:

Related Videos

Stocks

Referenced

100%
100%

Most Active by Volume

89,970,926
  • $16.15 ▲ 0.12%
77,131,582
  • $58.94 ▼ 1.31%
67,336,935
  • $26.56 ▲ 1.68%
48,814,124
  • $86.20 ▲ 0.02%
47,526,126
  • $23.21 ▲ 0.78%
44,660,424
  • $23.91 ▲ 6.36%
38,799,699
  • $4.289 ▲ 4.36%
36,199,890
  • $40.01 ▼ 0.97%
As of 4/17/2014, 04:07 PM